Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 2,10 M
EBIT 2016 -57,5 M
Net income 2016 -65,7 M
Debt 2016 -
Yield 2016 -
Sales 2017 5,47 M
EBIT 2017 -60,4 M
Net income 2017 -58,3 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 38,2x
Capi. / Sales2017 14,6x
Capitalization 80,1 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
12/08 BIOTECH MOVERS AND SHAKERS : Cascadian Therapeutics, Inc. (NASDAQ:CASC) and Anth..
12/07 ANTHERA PHARMACEUTICALS : Pharma Appoints New CEO; Other Exec Changes Announced
12/06 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Departure of Directors..
12/06 ANTHERA PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
12/06 Anthera Announces Leadership Transition in Preparation of Commercialization o..
12/06 Anthera Reports Blisibimod BRIGHT-SC IgA Nephropathy Continues to Demonstrate..
12/01 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Regulation FD Disclosu..
12/01 ANTHERA PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)
11/30 WEDNESDAY SECTOR LAGGARDS : Precious Metals, Biotechnology Stocks
11/11 ANTHERA PHARMACEUTICALS : Announces that the Blisibimod CHABLIS-SC1 Phase 3 Stud..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 6,80 $
Spread / Average Target 256%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Paul F. Truex Chief Executive Officer & Director
John Craig Thompson President & Chief Operating Officer
Christopher S. Henney Chairman
May Liu CAO, Senior VP-Finance & Administration
Chuck Olson Chief Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR80
AMGEN, INC.-11.63%106 716
GILEAD SCIENCES, INC.-28.16%95 779
CELGENE CORPORATION-5.25%87 962
REGENERON PHARMACEUTIC..-31.32%39 322
ACTELION LTD50.21%22 204
More Results